Study of Pelvic Hypofractionated Radiotherapy in Endometrial Cancer

This study will investigate if a shorter treatment course (known as "hypofractionation") for pelvic radiation is safe for women with endometrial cancer. Doctors leading the study will also determine the safest and most tolerable dose of shortened radiation (hypofractionation) used to treat women in this study. Because this study will shorten the radiation course typically used to treat endometrial cancer, each daily treatment given to women in this study will be slightly higher than normal to ensure that the total radiation dose they receive is still effective and similar to the radiation dose

Trial Details

NCT ID
NCT04683653
Phase
PHASE1 / PHASE2
Sponsor
University of Chicago
Status
RECRUITING
Cancer Type
Uterine Cancer
Interventions
  • Hypofractionated Radiation
  • Clinical Follow-Up and Assessments
Locations (sample)
  • Atlanta, Georgia, United States|33.749,-84.38798
  • Chicago, Illinois, United States|41.85003,-87.65005
  • Chicago, Illinois, United States|41.85003,-87.65005
  • Houston, Texas, United States|29.76328,-95.36327
  • Salt Lake City, Utah, United States|40.76078,-111.89105

Key Eligibility Criteria

  • Diagnosis of primary cervical cancer or uterine cancer of any histology
  • Age ≥ 18 years.
  • Non-metastatic disease according to the International Federation of Gynecology and Obstetrics (FIGO).
  • Must have been treated with definitive intent, including standard-of-care hysterectomy, without any gross residual disease post-operatively. Nodal …

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Uterine Cancer Trials on Trialify →